Get started
Author

Reinhard Marks

Observed names: Marks, R, R Marks, R. Marks, Reinhard E. Marks
ORCID: 0000-0001-9513-7971
Observed ORCID: 0000-0001-9513-7971
OpenAlex ID: A5084494517
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial
2019 · Viola Poeschel, Gerhard Held, et al. · The Lancet · 254
PDF
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
2015 · Gerhard Zugmaier, Nicola Gökbuget, et al. · Blood · 163
Efficacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting
2009 · M Lübbert, H Bertz, et al. · Bone Marrow Transplantation · 99
Non-intensive treatment with low-dose 5-aza-2′-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients
2009 · M Lübbert, H Bertz, et al. · Bone Marrow Transplantation · 90
5-Azacytidine and DLI can induce long-term remissions in AML patients relapsed after allograft
2015 · J Steinmann, H Bertz, et al. · Bone Marrow Transplantation · 82
Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab
2019 · Sebastian Rauer, Reinhard Marks, et al. · New England Journal of Medicine · 80
Allogeneic stem cell transplantation for myelodysplastic syndromes with bone marrow fibrosis
2010 · N. Kroger, T. Zabelina, et al. · Haematologica · 65
PDF
Signaling by small GTPases in the immune system
2007 · Juergen S. Scheele, Reinhard E. Marks, et al. · Immunological Reviews · 61
Prognostic Factor and Quality of Life Analysis in 160 Patients Aged ≥60 Years with Hematologic Neoplasias Treated with Allogeneic Hematopoietic Cell Transplantation
2010 · Barbara Deschler, Kristin Binek, et al. · Transplantation and Cellular Therapy · 48
Targeting TGFβ-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome
2024 · Janaki Manoja Vinnakota, Francesca Biavasco, et al. · Nature Cancer · 44
Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation
2018 · Sebastian Sommer, Marjan Cruijsen, et al. · Leukemia Research · 40
PDF
Altered Spectrum of Lymphoid Neoplasms in a Single-Center Cohort of Common Variable Immunodeficiency with Immune Dysregulation
2021 · Claudia Wehr, Leonora Houet, et al. · Journal of Clinical Immunology · 33
PDF
Prognostic factors for survival after allogeneic transplantation in acute lymphoblastic leukemia
2020 · C. Greil, M. Engelhardt, et al. · Bone Marrow Transplantation · 33
PDF
Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries
2023 · Miguel Á. Canales Albendea, Pier Luigi Canonico, et al. · Frontiers in Medicine · 30
Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis
2021 · Andrés R. Rettig, Gabriele Ihorst, et al. · Annals of Hematology · 29
PDF
Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study
2022 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Clinical Cancer Research · 28
PDF
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
2022 · Andrea Keppler-Hafkemeyer, Christine Greil, et al. · Nature Cancer · 27
PDF
Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis
2015 · K. Lerch, A. H. Meyer, et al. · Annals of Hematology · 27
Impact of Lung Function on Bronchiolitis Obliterans Syndrome and Outcome after Allogeneic Hematopoietic Cell Transplantation with Reduced-Intensity Conditioning
2018 · Jesús Duque-Afonso, Gabriele Ihorst, et al. · Transplantation and Cellular Therapy · 26
Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
2023 · Maria-Luisa Schubert, Wolfgang A. Bethge, et al. · Blood Advances · 24
PDF
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single‐centre analysis
2020 · Eliza M. Lauer, Miguel Waterhouse, et al. · British Journal of Haematology · 24
PDF
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
2023 · Grzegorz S. Nowakowski, Dok Hyun Yoon, et al. · Annals of Hematology · 23
Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation
2013 · J Duque-Afonso, G Ihorst, et al. · Bone Marrow Transplantation · 23
TIM‐3 deficiency presenting with two clonally unrelated episodes of mesenteric and subcutaneous panniculitis‐like T‐cell lymphoma and hemophagocytic lymphohistiocytosis
2020 · Oliver Wegehaupt, Miriam Groß, et al. · Pediatric Blood & Cancer · 22
PDF
Long-term complete remission of refractory severe idiopathic immune thrombocytopenia (ITP) treated with daratumumab
2022 · Tim Strüßmann, Johannes Jung, et al. · Annals of Hematology · 21
PDF
Works count: 115
Citation count: 1,788
H-index: 23
I10-index: 40
Year
Topic
Type